Switzerland-based NovImmune has begun dosing in a Phase I trial of a monoclonal antibody drug candidate NI-0101, with healthy volunteers.

The first-in-human study will evaluate the pharmacokinetic, pharmacodynamic, safety and tolerability profile of the drug candidate targeting toll-like receptor-4 (TLR4).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

NovImmune chief medical officer Cristina de Min said; "Data generated during this Phase I program, coupled with the information from pre-clinical experiments in relevant animal models for human diseases, will build a solid foundation to advance NI-0101 into Phase II studies."

"The first-in-human study will evaluate the pharmacokinetic, pharmacodynamic, safety and tolerability profile of the drug candidate targeting toll-like receptor-4 (TLR4)."

In various preclinical models of arthritis, respiratory inflammation, organ injury and other autoimmune and inflammatory conditions, NI-0101 demonstrated efficacy of TLR4 blockade.

NI-0101 inhibits the ability of the subunits of the receptor complex to function together, thereby suppressing TLR4 signalling in spite of the pro-inflammatory signal.

See Also:

TLR4 is a well characterised toll-like receptor with an important role as a key mediator of acute and chronic inflammation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Together with other receptors, TLR4 generally plays a role in fighting invasions by responding to bacterial lipopolysaccharide as a pro-inflammatory stimulus.

When the body faces continuous inflammation, the cells get damaged and the products of damaged cells send pro-inflammatory signals by means of TLR4.

Such signals lead to self damage and inflammation which is the major reason behind several diseases. NI-0101 is designed to interrupt this activity, according to NovImmune.